Quantcast
Last updated on April 17, 2014 at 13:22 EDT

Latest Eisai Stories

2013-06-20 08:26:47

WOODCLIFF LAKE, NJ and SAN DIEGO, CA, June 20, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that data from the BELVIQ(®) (lorcaserin HCl) Phase 3 clinical trial program will be presented at the following scientific meeting: American Diabetes Association's 73rd Scientific SessionsChicago: June 21-25, 2013 Lorcaserin HCl Phase 3 Trials in Obese and Overweight Patients: Week 52 Outcomes for Those Achieving at Least 5% Weight Loss at Week 12...

2013-06-14 08:25:41

WOODCLIFF LAKE, N.J. and SAN DIEGO, June 14, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), announced today that data from the BELVIQ(®) (lorcaserin HCl) Phase 3 clinical trial program will be presented at the following scientific meeting: ENDO 2013, the Endocrine Society's 95th Annual Meeting & ExpoSan Francisco: June 15-18, 2013 Association of Changes in Glycemic- and Lipid-Related Cardiometabolic Risk Factors and Weight Loss in Pooled Lorcaserin...

2013-06-13 12:27:51

Former Secretary of State and Epilepsy Advocate Hillary Rodham Clinton to Speak as This Year's Guest of Honor WOODCLIFF LAKE, N.J., June 13, 2013 /PRNewswire/ -- Eisai Inc. announced today its platinum level sponsorship of the Citizens United for Research in Epilepsy (CURE) 15(th) Annual Chicago Benefit taking place Thursday, June 13, at Navy Pier, Chicago, IL. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) CURE is a nonprofit organization focused on finding a...

2013-06-07 08:25:13

-- BELVIQ Available in US Pharmacies within One Week -- SAN DIEGO, June 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported today on the launch of BELVIQ (pronounced BEL-VEEK) in the United States. BELVIQ will be available to patients by prescription in US pharmacies beginning June 11. Eisai Inc. is responsible for the marketing and distribution of BELVIQ under its agreement with Arena Pharmaceuticals GmbH, a wholly owned subsidiary of Arena Pharmaceuticals,...

2013-06-07 08:24:52

BELVIQ Available in U.S. Pharmacies within One Week WOODCLIFF LAKE, N.J., June 7, 2013 /PRNewswire/ -- Eisai Inc. announced today that BELVIQ (pronounced BEL-VEEK) will be available to eligible patients by prescription in the United States beginning June 11. To view the multimedia assets associated with this release, please visit: http://www.multivu.com/mnr/60316-eisai-belviq-civ-chronic-weight-management-tablets-for-overweight-adults (Photo:...

2013-05-16 16:25:39

WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Eisai Inc. announced today that nine abstracts highlighting new study results in melanoma, breast and endometrial cancer will be presented during the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 31 - June 4, 2013. (Logo: http://photos.prnewswire.com/prnh/20120413/MM87168LOGO ) "These studies reinforce Eisai's strong and growing commitment to oncology, particularly to...

2013-05-16 12:30:24

Will Lead Commercial Strategy for Eisai's Subsidiary in Mexico WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the appointment of Ricardo Gonzalez Balboa to the position of General Manager, Eisai Laboratorios, S. de R.L. de C.V. (Eisai Mexico), a direct subsidiary of Eisai Inc. In this position, Mr. Gonzalez Balboa will further develop and implement the company's commercial strategy in Mexico....

2013-05-16 04:23:41

Data to Be Presented at Annual Meeting of the American Society of Clinical Oncology (ASCO) LUGANO, Switzerland and WOODCLIFF LAKE, N.J., May 16, 2013 /PRNewswire/ -- Helsinn Group and Eisai Inc. announced today top-line results from Helsinn's pivotal clinical studies investigating the oral fixed-dose combination of netupitant and palonosetron (NEPA) being evaluated for the proposed indication of prevention of chemotherapy-induced nausea and vomiting (CINV). These data will be...

2013-05-07 16:28:22

-- Arena to Receive $65 Million in Milestone Payments from Eisai -- SAN DIEGO, May 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the Office of the Federal Register filed for public inspection the US Drug Enforcement Administration's (DEA) final rule placing BELVIQ( )(pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. The scheduling designation will be effective 30 days after tomorrow's expected publication in the Federal...

2013-04-18 08:30:33

-- 4 Paws for Ability Service Dogs to Greet Visitors at Eisai Event Booth -- WOODCLIFF LAKE, N.J., April 18, 2013 /PRNewswire/ -- Eisai Inc. announced today that it is a silver level sponsor of the Epilepsy Foundation's 7(th) Annual National Walk for Epilepsy, a family-oriented, non-competitive event to raise awareness and funds to continue fighting to stop seizures, find a cure and overcome the challenges created by epilepsy. The Walk, which unites thousands of families living with...